Bedrocan - THC 22% | CBD <1.0%

Bedrocan - THC 22% |  CBD <1.0%
Product Description

Introduced in 2003, Bedrocan® is  the brand name for the cultivar Cannabis sativa L. ‘Afina’. Cannabis sativa L. ‘Afina’ is the first cultivar developed and it features 22% THC, with a CBD-level below 1%. It’s the most widely used medicinal cannabis product and has been used in more research than other products. Bedrocan® is available in flos form.

Bedrocan

  • NL
  • 2018
    On CPHI since
  • 2
    Certificates
  • 50 - 99
    Employees
Company types
Manufacturer/Innovator
Primary activities
API Producer
Specifications
  • Selling Points
    Brand Name; Green Product; International Approvals/Standards; Product Features; Product Performance; Reputation
  • Model
    THC 22% | CBD <1.0%
  • Supplied from
    Netherlands

Bedrocan

  • NL
  • 2018
    On CPHI since
  • 2
    Certificates
  • 50 - 99
    Employees
Company types
Manufacturer/Innovator
Primary activities
API Producer

More Products from Bedrocan (2)

  • Bedrolina®-  THC 14% | CBD <1.0%

    Product Bedrolina®- THC 14% | CBD <1.0%

    Introduced in 2024, Bedrolina® Bedrolina® is the brand name for the indica cultivar Cannabis sativa L. ‘Janna’, and it is the most recent product launched in our portfolio. Cannabis sativa L. ‘Janna’ was developed to supply a product with higher CBD content that facilitat...
  • Bediol - THC 6.3% | CBD 8%

    Product Bediol - THC 6.3% | CBD 8%

    Introduced in 2007, Bediol® is the brand name for the cultivar Cannabis sativa L. ‘Elida’. Cannabis sativa L. ‘Elida’ is one of the first cannabis cultivars developed specifically to have a higher CBD content. The effects of CBD are distinctly different from THC. Bediol® has a balanced...

Bedrocan resources (2)

  • News Bedrocan develops new practice for cannabis cultivation

    Bedrocan has developed a new practice for medicinal cannabis cultivation. The practice is already in use at Bedrocan’s facilities and is called GMCCP: Good Medicinal Cannabis Cultivation Practice. According to Bedrocan, GACP is not sufficient for cannabis intended for medicinal use, hence the need for a special practice for the cultivation of medicinal cannabis.


  • Webinar Cannabis-based medicine and chronic pain

    Monique van Velzen is research manager, assistant professor and supervisor of medical researchers at the Anesthesiology department of the LUMC in Leiden, Netherlands. Her research focuses on understanding patients with (chronic) pain better and studying the most optimal form of pain relief. Since 2017, Monique has been supervising research into medicinal cannabis for specific types of pain. For more information about the webinars, visit www.bedrocan.com/series